View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Prospect Capital Announces Annual Meeting Update

Prospect Capital Announces Annual Meeting Update NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 16, 2025. The proposals that were considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on September 18, 2025 (the “Proxy”). As of September 17, 2025, there were 465,087,009 shares of the Company's common st...

Snap Inc: 1 director

A director at Snap Inc sold 1,259,900 shares at 8.000USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare...

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...

 PRESS RELEASE

Prospect Capital Announces Financial Results for September 2025

Prospect Capital Announces Financial Results for September 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended September 30, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted averagebasis for period numbers)Quarter EndedQuarter EndedQuarter EndedSeptember 30, 2025June 30, 2025September 30, 2024    Net Investment Income (“NII”)$79,350$79,043$89,877NII per Common Share$0.17$0.17$0.21Interest as % of Total Investmen...

Dan Salmon
  • Dan Salmon

Snap Inc. (SNAP, Neutral, $8 target) Revenue growth in-line, and Perpl...

What’s New: In this first take following tonight’s results, we focus on: 1. Stock pops on improved results and surprise Perplexity deal 2. DR recovers & continued enthusiasm for SMBs, but large advertisers down 3. North America DAUs steady but we remain cautious as age verification rolls out 4. Perplexity boosts the AI narrative 5. Very good cost control and margins

 PRESS RELEASE

Prospect Capital Schedules First Fiscal Quarter Earnings Release and C...

Prospect Capital Schedules First Fiscal Quarter Earnings Release and Conference Call NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended September 30, 2025 and to issue its earnings press release on Thursday, November 6, 2025, after the close of the markets. The Company will host a conference call on Friday, November 7, 2025 at 9:00 a.m. Eastern Time. The conference call dia...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 31, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health Reports Third Quarter 2025 Business Highlights and Financi...

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration wi...

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multi...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for ...

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein  Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical trial () with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology...

Dan Salmon
  • Dan Salmon

Snap Inc. (SNAP, Neutral, $8 target) Downgrade to Neutral on lower DR...

We are downgrading SNAP to Neutral from Buy and our target declines to $8 from $11. Direct Response Ad Business Evolving: Our prior Buy thesis was anchored by SNAP’s improved direct response ad offering and was helped by growth of its small advertiser base over the past year-plus. However, DR ad growth faded to +5% in 2Q25 from mid-teens, and our channel checks remain mixed.

 PRESS RELEASE

Prospect Capital Corporation Announces Pricing of $167 Million 5.5% Ov...

Prospect Capital Corporation Announces Pricing of $167 Million 5.5% Oversubscribed Institutional Unsecured Notes Offering NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) announced today that Prospect priced an institutional offering of approximately $167 million in aggregate principal amount of 5.5% Series A Notes due 2030 (the “Notes”) on October 27, 2025. “We appreciate the strong support and interest we received from over 40 institutional investors for this oversubscribed unsecured bond offering,” said Grier Eliasek,...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch